Skip to main content Skip to footer
American Family Children's Hospital
Tracy M. Downs, MD, FACS close
Tracy M. Downs, MD, FACS

New Patients

Need help selecting a primary care doctor? Contact the Welcome Center for personal assistance.

For Referring Physicians

How to refer a patient

Tracy M. Downs, MD, FACS Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Downs is a urologic surgeon and fellowship-trained specialist in urologic oncology. He performs specialized surgery for complex cancers of the genitourinary tract, including robotic cystectomy and other minimally invasive procedures. He has a special interest in the treatment of bladder cancer, and directs the UW Bladder Cancer and Intravescial Therapy Programs. 



Bladder Cancer


Genitourinary Cancer (Bladder, Kidney, Prostate, Testicular)

Kidney Cancer


Orthotopic Neobladder

Prostate Brachytherapy


Robotic Cystectomy

Robotic Prostatectomy

Testicular Cancer


Urinary Reconstruction Surgery



University Hospital
(608) 263-4757 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital
UnityPoint Health - Meriter
Veterans Hospital - Wm. S. Middleton Memorial

UW School of Medicine and Public Health

Department of Urology

Professional Certifications and Education

Board Certification Urology
Fellowship Urologic Oncology, University of California San Francisco Medical Center, San Francisco, CA, 2003
Residency Brigham and Women's Hospital, Boston, MA
Medical School University of California, San Diego School of Medicine, La Jolla, CA

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Downs has a joint appointment with the UW Carbone Cancer Center where his translational research focuses on discovery of molecular and urinary biomarkers for bladder cancer and his clinical research focuses on developing new therapies for genitourinary cancers.

PubMed Articles
Downs TM Weissert JA Ravvaz K Can we improve non-muscle-invasive bladder cancer (NMIBC) guideline adherence with smarter risk-stratification? J Urol . 2018 Jun 12;
[PubMed ID: 29906436]
Maciolek KA Best SL Lopez V Posielski N Knoedler M Bushman WA Jarrard DF Downs TM Abel EJ Richards KA Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort. Urol Oncol . 2018 Jun 7;
[PubMed ID: 29887242]
Harshman LC Tripathi A Kaag M Efstathiou JA Apolo AB Hoffman-Censits JH Stadler WM Yu EY Bochner BH Skinner EC Downs T Kiltie AE Bajorin DF Guru K Shipley WU Steinberg GD Hahn NM Sridhar SS Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clin Genitourin Cancer . 2018 Jun;16(3):213-218
[PubMed ID: 29289519]
Daneshmand S Patel S Lotan Y Pohar K Trabulsi E Woods M Downs T Huang W Jones J O'Donnell M Bivalacqua T DeCastro J Steinberg G Kamat A Resnick M Konety B Schoenberg M Jones JS Flexible Blue Light Study Group Collaborators. Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J Urol . 2018 May;199(5):1158-1165
[PubMed ID: 29203268]
Richards KA Ruiz VL Murphy DR Downs TM Abel EJ Jarrard DF Singh H Diagnostic evaluation of patients presenting with hematuria: An electronic health record-based study. Urol Oncol . 2018 Mar;36(3):88.e19-88.e25
[PubMed ID: 29169843]
Shore ND Boorjian SA Canter DJ Ogan K Karsh LI Downs TM Gomella LG Kamat AM Lotan Y Svatek RS Bivalacqua TJ Grubb RL 3rd Krupski TL Lerner SP Woods ME Inman BA Milowsky MI Boyd A Treasure FP Gregory G Sawutz DG Yla-Herttuala S Parker NR Dinney CPN Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol . 2017 Oct 20;35(30):3410-3416
[PubMed ID: 28834453]
Spiess PE Agarwal N Bangs R Boorjian SA Buyyounouski MK Clark PE Downs TM Efstathiou JA Flaig TW Friedlander T Greenberg RE Guru KA Hahn N Herr HW Hoimes C Inman BA Jimbo M Kader AK Lele SM Meeks JJ Michalski J Montgomery JS Pagliaro LC Pal SK Patterson A Plimack ER Pohar KS Porter MP Preston MA Sexton WJ Siefker-Radtke AO Sonpavde G Tward J Wile G Dwyer MA Gurski LA Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw . 2017 Oct;15(10):1240-1267
[PubMed ID: 28982750]
Ravvaz K Walz ME Weissert JA Downs TM Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population. J Urol . 2017 Oct;198(4):824-831
[PubMed ID: 28433642]
Blute ML Jr Kucherov V Rushmer TJ Damodaran S Shi F Abel EJ Jarrard DF Richards KA Messing EM Downs TM Reduced estimated glomerular filtration rate (eGFR &lt;60 mL/min/1.73 m<sup>2</sup> ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int . 2017 Sep;120(3):387-393
[PubMed ID: 28464520]
Tobert CM Hamilton-Reeves JM Norian LA Hung C Brooks NA Holzbeierlein JM Downs TM Robertson DP Grossman R Nepple KG Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications for Cystectomy in Bladder Cancer. J Urol . 2017 Sep;198(3):511-519
[PubMed ID: 28286066]
Tazeh NN Scott K Damodaran S Huang W Downs TM Chondroma of the Bladder: A Case Report and Review of the Literature. Urology . 2017 Aug;106:e9-e10
[PubMed ID: 28479478]
Wang JH Downs TM Jason Abel E Richards KA Jarrard DF Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies. Curr Urol Rep . 2017 Jul;18(7):48
[PubMed ID: 28589399]
Gee JR Saltzstein DR Kim K Kolesar J Huang W Havighurst TC Wollmer BW Stublaski J Downs T Mukhtar H House MG Parnes HL Bailey HH A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers. Cancer Prev Res (Phila) . 2017 May;10(5):298-307
[PubMed ID: 28325826]
Tazeh NN Canter DJ Damodaran S Rushmer T Richards KA Abel EJ Jarrard DF Downs TM Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences. Bladder Cancer . 2017 Apr 27;3(2):89-94
[PubMed ID: 28516153]
Lane GI Downs TM Soubra A Rao A Hemsley L Laylan C Shi F Konety B Tolerability of Repeat Use of Blue Light Cystoscopy with Hexaminolevulinate for Patients with Urothelial Cell Carcinoma. J Urol . 2017 Mar;197(3 Pt 1):596-601
[PubMed ID: 27664580]
Blute ML Jr Damaschke N Wagner J Yang B Gleave M Fazli L Shi F Abel EJ Downs TM Huang W Jarrard DF Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS One . 2017;12(2):e0172048
[PubMed ID: 28234906]
Blute ML Jr Ziemlewicz TJ Lang JM Kyriakopoulos C Jarrard DF Downs TM Grimes M Shi F Mann MA Abel EJ Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology . 2017 Feb;100:139-144
[PubMed ID: 27667156]
Grimes MD Blute ML Jr Wittmann TA Mann MA Zorn K Downs TM Shi F Jarrard DF Best SL Richards KA Nakada SY Abel EJ A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. Urology . 2016 Oct;96:93-98
[PubMed ID: 27339026]
Jarrard D Konety B Huang W Downs T Kolesar J Kim KM Havighurst T Slaton J House MG Parnes HL Bailey HH Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D<sub>3</sub>) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. Am J Clin Exp Urol . 2016;4(2):17-27
[PubMed ID: 27766277]
Blute ML Jr Zorn K Grimes M Shi F Downs TM Jarrard DF Best SL Richards K Nakada SY Abel EJ Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. BJU Int . 2016 Sep;118(3):399-407
[PubMed ID: 26589741]